Get the Stockscreener App
0.7572
11.45%
0.0778
After Hours:
.77
0.0128
+1.69%
Cue Biopharma Inc stock is traded at $0.7572, with a volume of 1.50M.
It is up +11.45% in the last 24 hours and up +4.80% over the past month.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.
See More
Previous Close:
$0.6794
Open:
$0.68
24h Volume:
1.50M
Relative Volume:
3.00
Market Cap:
$33.56M
Revenue:
$3.82M
Net Income/Loss:
$-51.89M
P/E Ratio:
-0.5962
EPS:
-1.27
Net Cash Flow:
$-39.52M
1W Performance:
+58.01%
1M Performance:
+4.80%
6M Performance:
-59.94%
1Y Performance:
-67.08%
1-Day Range:
$0.68
$0.77
1-Week Range:
$0.45
$0.77
52-Week Range:
$0.45
$3.2491
Cue Biopharma Inc Stock (CUE) Company Profile
Name
Cue Biopharma Inc
Sector
Industry
Phone
617-949-2680
Address
40 GUEST STREET, BOSTON, MA
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Nov-21-22 | Initiated | Piper Sandler | Overweight |
| Jan-13-22 | Initiated | H.C. Wainwright | Buy |
| Jan-03-22 | Initiated | Craig Hallum | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Apr-09-20 | Initiated | Stifel | Buy |
| Jan-28-20 | Initiated | BTIG Research | Buy |
| Jan-22-20 | Initiated | JMP Securities | Mkt Outperform |
View All
Cue Biopharma Inc Stock (CUE) Latest News
What to expect from Cue Biopharma Inc’s (CUE) current quarter earnings? - US Post News
Cue Biopharma Inc (CUE) Stock: A Year of Highs and Lows - The InvestChronicle
Form 424B5 Cue Biopharma, Inc. - StreetInsider.com
Wall Street SWOT: Cue Biopharma stock pivots to autoimmune focus amid restructuring - Investing.com
Cue Biopharma prices $12M stock offering - MSN
Cue Biopharma Announces Pricing of $12.0 Million Public Offering - StockTitan
Cue Biopharma Announces Pricing of $12.0 Million Public Offering - GlobeNewswire
Cue Biopharma Announces Proposed Public Offering - The Bakersfield Californian
Cue Biopharma Announces Proposed Public Offering - GlobeNewswire
Cue Biopharma launches public stock offering By Investing.com - Investing.com Australia
Cue biopharma announces proposed public offering - MSN
Cue Biopharma Announces Proposed Public Offering - StockTitan
Universal Music Group establishes new division in China’s Greater Bay Area, led by Gary Chan - Music Business Worldwide
Universal Music China Greater Bay Area launches to 'drive forward Chinese pop' - Music Week
UMG Muscles Into Hong Kong and Macau with ‘Universal Music China Greater Bay Area (UMCGBA)’ - Digital Music News
UNIVERSAL MUSIC GROUP LAUNCHES UNIVERSAL MUSIC CHINA GREATER BAY AREA - PR Newswire
Reason why UXIN stock surged today and could keep going - Journal Transcript
Cue Biopharma stock plunges to 52-week low of $0.53 By Investing.com - Investing.com Australia
Cue Biopharma stock plunges to 52-week low of $0.53 By Investing.com - Investing.com South Africa
Cue Biopharma stock plunges to 52-week low of $0.53 By Investing.com - Investing.com Canada
Cue Biopharma stock plunges to 52-week low of $0.53 - Investing.com
Cue Biopharma stock plunges to 52-week low of $0.53 - Investing.com India
Cue Biopharma names J&J vet Lucinda Warren as CBO - The Pharma Letter
Cue Biopharma names Lucinda Warren as new chief business officer - Investing.com
Cue Biopharma names Lucinda Warren as new chief business officer - Investing.com India
Cue Biopharma names Lucinda Warren as new chief business officer By Investing.com - Investing.com Canada
Cue Biopharma names Lucinda Warren as new chief business officer By Investing.com - Investing.com UK
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer - GlobeNewswire
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer - GlobeNewswire Inc.
Cue Biopharma stock plunges to 52-week low at $0.58 amid market challenges - Investing.com
Cue Biopharma stock plunges to 52-week low at $0.58 amid market challenges - Investing.com India
Cue Biopharma announces director Michael J. Fox's resignation - Investing.com
Cue Biopharma announces director Michael J. Fox's resignation - Investing.com India
Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference - GlobeNewswire
Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference - StockTitan
Cue Biopharma Inc (CUE) Stock: Exploring a Year of Highs, Lows, and Trading Volume - The InvestChronicle
Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates - MSN
Stifel lowers Cue Biopharma shares target amid new strategy and funding needs - Investing.com Canada
Piper Sandler maintains confidence in Cue Biopharma stock as CUE-401 advances - Investing.com Canada
Q2 2024 Cue Biopharma Inc Earnings Call - Yahoo Finance
Cue Biopharma, Inc. (NASDAQ:CUE) Q2 2024 Earnings Call Transcript - Insider Monkey
CUE (Cue Biopharma) Volatility : 52.63% (As of Aug. 20, 2024) - GuruFocus.com
Cue Biopharma Inc (CUE) Q2 2024 Earnings Call Transcript Highlig - GuruFocus.com
Q2 2024 Cue Biopharma Inc Earnings Call Transcript - GuruFocus.com
Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
CUECue Biopharma, Inc. Latest Stock News & Market Updates - StockTitan
Cue Biopharma, Inc. (NASDAQ:CUE) Q2 2024 Earnings Call Transcript - MSN
Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights - ForexTV.com
Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights - StockTitan
Cue Biopharma (STU:1UC) Total Inventories : €0.00 Mil (As of Jun. 2024) - GuruFocus.com
Cue Biopharma (STU:1UC) 3-Year FCF Growth Rate : 8.90% (As of Jun. 2024) - GuruFocus.com
Cue Biopharma Inc Stock (CUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):